Internal dosimetry as a tool for radiation protection of the patient in nuclear medicine

Biomedical Imaging and Intervention Journal

Volumn 3, Issue 2, 2007, Pages

  Stabin, Michael G ^a   Flux, G D ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO 1 PHENYLALANINE 3 TYROSINE OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO 1 PHENYLALANINE 3 TYROSINE OCTREOTIDE Y 90; DIAGNOSTIC AGENT; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SODIUM IODIDE I 131; SOMATOSTATIN DERIVATIVE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

ABSORPTION; B CELL LYMPHOMA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMAGE ANALYSIS; MONTE CARLO METHOD; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; RADIATION PROTECTION; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; RISK BENEFIT ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; THYROID CANCER; THYROID DISEASE;

EID: 57049088134     PISSN: None     EISSN: 18235530     Source Type: Journal    
DOI: 10.2349/biij.3.2.e28     Document Type: Review

References (76)

1. Snyder WS, Fisher HL Jr, Ford MR et al. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J Nucl Med 1969; Suppl 3:7-52.
2. International Commission on Radiological Protection. Task Group Report on Reference Man. Oxford: Pergamon Press, 1975. (ICRP Publication; 23).
3. International Commission on Radiological Protection. Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Elsevier Health, 2003. (ICRP Publication; 89).
4. Snyder W, Ford M, Warner G. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. New York: Society of Nuclear Medicine, 1978. (MIRD Pamphlet; 5).
5. Snyder W, Ford M, Warner G et al. A tabulation of dose equivalent per microcurie-day for source and target organs of an adult for various radionuclides. Oak Ridge National Laboratory, 1975; ORNL-5000.
6. Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photons sources. Oak Ridge, TN: Oak Ridge National Laboratory, 1987; ORNL/TM-8381 V1-V7.
7. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37(3):538-46.
8. Stabin M, Watson E, Cristy M et al. Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy. 1995; ORNL/ TM-12907.
9. Spiers FW. Beta dosimetry in trabecular bone. Mays CW, ed. Delayed Effects of Bone-Seeking Radionuclides. Salt Lake City, UT: Univ of Utah Press, 1969: 95-108.
10. Eckerman KF, Stabin MG. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys 2000; 78(2):199-214.
11. Bouchet LG, Bolch WE, Howell RW et al. S values for radionuclides localized within the skeleton. J Nucl Med 2000; 41(1):189-212.
12. Stabin MG, Eckerman KF, Bolch WE et al. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 2002; 17(4):427-33.
13. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46(6):1023-7.
14. Siegel JA, Thomas SR, Stubbs JB et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40(2):37S-61S.
15. Buvat I, Rodriguez-Villafuerte M, Todd-Pokropek A et al. Comparative assessment of nine scatter correction methods based on spectral analysis using Monte Carlo simulations. J Nucl Med 1995; 36(8):1476-88.
16. Guy MJ, Castellano-Smith IA, Flower MA. DETECT - Dual energy transmission estimation CT - for improved attenuation correction in SPECT and PET. IEEE Trans Nucl Sci 1998; 45:1261-7.
17. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; 25:638-43.
18. Fleming JS. A technique for using CT images in attenuation correction and quantification in SPECT. Nucl Med Commun 1989; 10(2):83-97.
19. Autret D, Bitar A, Ferrer L et al. Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy. Cancer Biother Radiopharm 2005; 20(1):77-84.
20. Dewaraja YK, Wilderman SJ, Ljungberg M et al. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med 2005; 46(5):840-9.
21. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58(690):515-28.
22. Sachs RK, Hahnfeld P, Brenner DJ. The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/ misrepair. Int J Radiat Biol 1997; 72(4):351-74.
23. Lea DE, Catcheside DG. The Mechanism of the Induction by Radiation of Chromosome Abberations in Tradescantia. J Genet 1942; 44:216-45.
24. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8(11):1981-97.
25. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62(740):679-94.
26. Malaroda A, Flux GD, Buffa FM et al. Multicellular dosimetry in voxel geometry for targeted radionuclide therapy. Cancer Biother Radiopharm 2003; 18(3):451-61.
27. O'Donoghue JA, Sgouros G, Divgi CR et al. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 2000; 41(3):538-47.
28. Bodey RK, Evans PM, Flux GD. Application of the linearquadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59(1):228-41.
29. Blau M. Letter: Radiation dosimetry of 131-I-19-iodocholesterol: The pitfalls of using tissue concentration data. J Nucl Med 1975; 16(3):247-9.
30. Sgouros G, Kolbert KS, Sheikh A et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45(8):1366-72.
31. International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. New York: Pergamon, 1989. (ICRP Publication; 53).
32. International Commission on Radiological Protection. Radiation Dose To Patients From Radiopharmaceuticals. New York: Pergamon, 2000. (ICRP Publication; 80).
33. Xu XG, Chao TC, Bozkurt A. VIP-Man: an image-based wholebody adult male model constructed from color photographs of the Visible Human Project for multi-particle Monte Carlo calculations. Health Phys 2000; 78(5):476-86.
34. Segars JP. Development and Application of the New Dynamic NURBS-based Cardiac-Torso (NCAT) Phantom [Ph.D. Dissertation]. The University of North Carolina, 2001.
35. Kolbert KS, Sgouros G, Scott AM et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med 1997; 38(2):301-8.
36. Dewaraja YK, Wilderman SJ, Ljungberg M et al. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med 2005; 46(5):840-9.
37. Liu A, Williams LE, Lopatin G et al. A radionuclide therapy treatment planning and dose estimation system. J Nucl Med 1999; 40(7):1151-3.
38. Guy MJ, Flux GD, Papavasileiou P et al. RMDP: a dedicated package for 131I SPECT quantification, registration and patientspecific dosimetry. Cancer Biother Radiopharm 2003; 18(1):61-9.
39. Clairand I, Ricard M, Gouriou J et al. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med 1999; 40(9):1517-23.
40. Bielajew A, Rogers D. PRESTA: the parameter reduced electronstep transport algorithm for electron Monte Carlo transport. Nucl Instrum Methods 1987; B18:165-81.
41. Briesmeister JF, ed. MCNP - A General Monte Carlo N-Particle Transport Code, Version 4C. Los Alamos National Laboratory, 2000; LA-13709-M.
42. Allison J et al. Geant4 Developments and Applications. IEEE Trans Nucl Sci 2006; 53:270-8.
43. Lehmann J, Hartmann Siantar C, Wessol DE et al. Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system. Phys Med Biol 2005; 50(5):947-58.
44. Eschmann SM, Reischl G, Bilger K et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002; 29(6):760-7.
45. Canzi C, Zito F, Voltini F et al. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med Phys 2006; 33(8):2860-7.
46. Carlier T, Salaun PY, Cavarec MB et al. Optimized radioiodine therapy for Graves' disease: two MIRD-based models for the computation of patient-specific therapeutic 131I activity. Nucl Med Commun 2006; 27(7):559-66.
47. Grosso M, Traino A, Boni G et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm 2005; 20(2):218-23.
48. Furhang EE, Larson SM, Buranapong P et al. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999; 40(1):131-6.
49. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 1997; 7(2):183-7.
50. Reiners C. Radioiodine therapy of thyroid cancer. Tumordiagnostik & Therapie 1998; 19:70-3.
51. Benua RS, Cicale NR, Sonenberg M et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87:171-82.
52. Ott RJ, Tait D, Flower MA et al. Treatment planning for 131ImIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol 1992; 65(777):787-91.
53. Sgouros G, Kolbert KS, Sheikh A et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45(8):1366-72.
54. Dorn R, Kopp J, Vogt H et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003; 44(3):451-6.
55. Hanscheid H, Lassmann M, Luster M et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47(4):648-54.
56. Lassmann M, Luster M, Hanscheid H et al. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004; 45(4):619-25.
57. Sisson JC, Avram AM, Lawson SA et al. The so-called stunning of thyroid tissue. J Nucl Med 2006; 47(9):1406-12.
58. Woolfenden JM. Thyroid stunning revisited. J Nucl Med 2006; 47(9):1403-5.
59. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 1999; 43(4):336-43.
60. Matthay KK, Panina C, Huberty J et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001; 42(11):1713-21.
61. Gaze MN, Chang YC, Flux GD et al. Feasibility of dosimetrybased high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005; 20(2):195-9.
62. Monsieurs M, Brans B, Bacher K et al. Patient dosimetry for 131IMIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging 2002; 29(12):1581-7.
63. Flux GD, Guy MJ, Papavasileiou P et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003; 18(1):81-7.
64. DeNardo GL, DeNardo SJ, Shen S et al. Factors affecting 131ILym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 1999; 40(8):1317-26.
65. Linden O, Tennvall J, Cavallin-Stahl E et al. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 1999; 5(10 Suppl):3287s-91s.
66. Chatal JF, Faivre-Chauvet A, Bardies M et al. Bifunctional antibodies for radioimmunotherapy. Hybridoma 1995; 14(2):125-8.
67. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998; 39(8 Suppl):14S-20S.
68. Wiseman GA, White CA, Sparks RB et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39(1-2):181-94.
69. Cremonesi M, Ferrari M, Chinol M et al. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. Q J Nucl Med 2000; 44(4):325-32.
70. Barone R, Walrand S, Valkema R et al. Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy. J Nucl Med 2002; 43:1267.
71. Esser JP, Krenning EP, Teunissen JJ et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33(11):1346-51.
72. EURATOM. Health protection of individuals against the dangers of ionising radiation in relation to medical exposure: Council directive 97/ 43. EURATOM, 1997.
73. Parthasarathy KL, Crawford ES. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy. J Nucl Med Technol 2002; 30(4):165-71; quiz 172-3.
74. Solans R, Bosch JA, Galofre P et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42(5):738-43.
75. Siegel JA, Stabin MG, Brill AB. The importance of patientspecific radiation dose calculations for the administration of radionuclides in therapy. Cell Mol Biol (Noisy-Le-Grand) 2002; 48(5):451-9.
76. Thierens HM, Monsieurs MA, Bacher K. Patient dosimetry in radionuclide therapy: the whys and the wherefores. Nucl Med Commun 2005; 26(7):593-9.